Today healthcare costs are following an upward trend. In containing those rising costs, one approach is to maximize outcomes or value for patients. In health care, patients’ value depends not only on clinical therapies but also on several non-clinical perspectives, which define whether clinical therapies are going to be beneficiary or problematic. Recently, healthcare research has emphasized to explore non-clinical perspectives in care processes. This research explored non-clinical perspectives of polypharmacy through some patients’ and physicians’ participation. Polypharmacy refers to the simultaneous use of multiple medications and is called necessary evil because of its association with several adverse consequences such as adverse drug events, drug-drug interactions, poor medication adherence, and additional health service expenditure. This research aimed to illustrate how physicians can reduce cases of polypharmacy or help patients in dealing with the adverse effects of this condition by focusing on non-clinical perspectives of polypharmacy. In this context, this research answered three specific questions: how patients experience consequences of polypharmacy; what causes polypharmacy; and what interventions should be appropriate to manage polypharmacy. This research collected qualitative data only, using a phenomenological approach. The unit of analysis was patients and physicians. The data were collected conducting in-depth naturalistic interviews with structured open-ended questionnaires. In analyzing the data, this research sought a comparative approach, in which the findings of this research have been compared to the findings in the literature. This research found that several non-clinical factors cause polypharmacy and trigger problematic phenomena in polypharmacy. Accordingly, several interventions that targeted those factors were proposed. Those interventions will likely add value for patients who are in polypharmacy or who are likely to experience polypharmacy. The added value will prevent some potential costs related to the utilization of additional health services and improve the care management process for patients in polypharmacy.